Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma
- Conditions
- Osteosarcoma RecurrentOsteosarcoma Metastatic
- Registration Number
- NCT04651179
- Brief Summary
A retrospective observational study of the effectiveness of gemcitabine - docetaxel in patients with relapsed osteosarcoma who have been treated with HD IFO in first line treatment
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
-
Age at diagnosis of high grade osteosarcoma >= 4
-
Received first line treatment with HD IFO
-
Following HD IFO treatment, they have been diagnosed refractory disease and they satisfy at least one of the following criteria :
- Relapsed in the first 24 month following the initial diagnosis, regardless of location and resectability
- Lung relapsed disease with more than 2 nodules diagnosed over 24 months from the initial diagnosis
- Non resectable relapsed disease diagnosed over 24 months from the initial diagnosis Before or during GEMDOX treatment, eligible patients may have been subject to metastasectomy
none
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to Gemcitabina - Docetaxel Treatment 12 months assessed as overall survival (12 months)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
AOUC Azienda Ospedaliero-Universitaria Careggi
๐ฎ๐นFlorence, Italy
IRCCS Istituto Nazionale dei Tumori
๐ฎ๐นMilan, Italy
Istituto Nazionale Tumori
๐ฎ๐นMilan, Milano, Italy
Fondazione del Piemonte per l' Oncologia IRCCS Candiolo
๐ฎ๐นCandiolo, Turin, Italy
Istituto Ortopedico Rizzoli
๐ฎ๐นBologna, Italy
AOU Cittร della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita
๐ฎ๐นTurin, Italy
Azienda Ospedaliero Universitaria pisana
๐ฎ๐นPisa, Italy
IRCCS Istituti Fisioterapici Ospitalieri
๐ฎ๐นRome, Italy